Lead Product(s): ACT-709478
Therapeutic Area: Neurology
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: $417.0 million Upfront Cash: $45.0 million
Deal Type: Licensing Agreement January 10, 2020
Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.